BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING

Executive Summary

• Bright Minds Biosciences Inc. has entered into an equity distribution agreement with Piper Sandler & Co. and Cantor Fitzgerald & Co. to establish an at-the-market (ATM) equity offering program.
• The ATM allows the company to offer and sell common shares with an aggregate offering price of up to US$100 million over a three-year period.
• Proceeds from the offering are intended for general corporate purposes, including sales and marketing, capital expenditures, product development, and working capital.

Key Details

• Transaction Structure: At-the-market (ATM) equity offering program.
• Agents: Piper Sandler & Co. and Cantor Fitzgerald & Co.
• Aggregate Offering Price: Up to US$100 million.
• Duration: Effective for a period of three years from the date of effectiveness of the Registration Statement, unless terminated earlier.
• Sales Mechanism: Shares may be sold from time to time in the United States through NASDAQ or other methods permitted by law under Rule 415 of the Securities Act of 1933.
• Use of Proceeds: General corporate purposes, specifically including expenses related to sales and marketing, capital expenditures, further product development, operational expenditures, and working capital.
• Regulatory Filing: The offering is made pursuant to a Registration Statement on Form F-3 (SEC File No. 333-289851), which was made effective on September 2, 2025.
• Discretion: The timing and extent of sales are at the discretion of the Company; total gross proceeds could be significantly less than US$100 million.